AdvanCell closed an oversubscribed $315 million Series D to advance targeted alpha therapies and expand manufacturing.
- Amount
- $315M
- Stage
- Series D
- Announced
- 15 July 2026
- Leads
- Ally Bridge Group, Alpha Wave
- Other investors
- Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price Associates, Inc., Eventide Asset Management, Velosity Capital, Morningside, Eli Lilly and Company, SV Health Investors, Sanofi Ventures, Abingworth
- Use of funds
- Advance ADVC001 toward Phase 3, expand Lead-212 platform, isotope supply and U.S. manufacturing infrastructure.
- Checked
- Amount and date checked against the press source